3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neoplasms
7
Carcinoma, Hepatocellular
7
Neoplasm Metastasis
5
Carcinoma, Non-Small-Cell Lung
5
Recurrence
4
Prostatic Neoplasms
4
Breast Neoplasms
4
Melanoma
3
Lymphoma, B-Cell, Marginal Zone
3
Lymphoma
3
Head and Neck Neoplasms
3
Sarcoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Polycystic Ovary Syndrome
2
Pleural Effusion, Malignant
2
Mesothelioma, Malignant
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Anxiety Disorders
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neuroblastoma
1
Nephrotic Syndrome
1
Neoplasms, Plasma Cell
1
NSCLC
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Interventions
Cyclophosphamide
101
Etoposide
60
Carboplatin
55
Vincristine
51
Filgrastim
49
Topotecan
44
Temozolomide
44
Melphalan
44
Isotretinoin
44
Doxorubicin
44
Irinotecan
42
Cisplatin
35
Peripheral Blood Stem Cell Transplantation
31
dinutuximab
29
Radiotherapy
29
Granulocyte Colony-Stimulating Factor
29
sargramostim
28
3-Iodobenzylguanidine
27
Granulocyte-Macrophage Colony-Stimulating Factor
25
Busulfan
22
Magnetic Resonance Spectroscopy
19
aldesleukin
18
Thiotepa
18
fludarabine
17
Interleukin-2
17
humanized 3F8 anti-GD2 monoclonal antibody
16
etoposide phosphate
16
Ifosfamide
15
naxitamab
14
fludarabine phosphate
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neuroblastoma
×
Pharmaceutical Preparations
×
Clear all
NCT07334301
2026-01-12
BEACON2
University of Birmingham
Phase 1/2
Recruiting
160 enrolled